Cargando…
ELABELA acts as a protective biomarker in patients with atrial fibrillation
BACKGROUND: Atrial fibrillation (AF) is the most common type of clinical arrhythmia. An early diagnosis can be beneficial in the prevention of complications, such as heart failure (HF) and stroke. In this study, we revealed that ELABELA (ELA) acts as a protective factor in patients with arrhythmia a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743407/ https://www.ncbi.nlm.nih.gov/pubmed/35070372 http://dx.doi.org/10.21037/jtd-21-1728 |
_version_ | 1784629897140895744 |
---|---|
author | Cui, Chunhong Zhou, Hongmei Xu, Jin |
author_facet | Cui, Chunhong Zhou, Hongmei Xu, Jin |
author_sort | Cui, Chunhong |
collection | PubMed |
description | BACKGROUND: Atrial fibrillation (AF) is the most common type of clinical arrhythmia. An early diagnosis can be beneficial in the prevention of complications, such as heart failure (HF) and stroke. In this study, we revealed that ELABELA (ELA) acts as a protective factor in patients with arrhythmia and could serve as a prognostic marker for AF and its associated complication of HF. METHODS: We tested the expression level of potential biomarkers including matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), and ELA with enzyme-linked immunosorbent assay (ELISA) in serum derived from 131 patients (patients with AF =103; patients with paroxysmal supraventricular tachycardia =28). The impact of clinical risk factors and biomarkers on AF occurrence was evaluated using binary logistic analysis. RESULTS: The ELA expression level was lower in AF patients than in the negative controls (P<0.0001). Expression of ELA was negatively correlated with brain natriuretic peptide (BNP) expression in all the samples. In the binary logistic analysis, high levels of BNP and lower levels of ELA were significantly associated with an increased risk of AF (P<0.0001) and could be used as prognostic markers for patients with AF. CONCLUSIONS: Expression of ELA showed a protective role in AF patients. The ELA level was negatively correlated with BNP levels, which has been shown to predict a high risk of HF independently and consistently. Additionally, lower levels of ELA were associated with a high risk of AF and HF in patients with arrhythmia. KEYWORDS: ELABELA (ELA); matrix metalloproteinase-9 (MMP-9); tissue inhibitor of metalloproteinase-1 (TIMP-1); atrial fibrillation (AF); brain natriuretic peptide (BNP) |
format | Online Article Text |
id | pubmed-8743407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-87434072022-01-21 ELABELA acts as a protective biomarker in patients with atrial fibrillation Cui, Chunhong Zhou, Hongmei Xu, Jin J Thorac Dis Original Article BACKGROUND: Atrial fibrillation (AF) is the most common type of clinical arrhythmia. An early diagnosis can be beneficial in the prevention of complications, such as heart failure (HF) and stroke. In this study, we revealed that ELABELA (ELA) acts as a protective factor in patients with arrhythmia and could serve as a prognostic marker for AF and its associated complication of HF. METHODS: We tested the expression level of potential biomarkers including matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), and ELA with enzyme-linked immunosorbent assay (ELISA) in serum derived from 131 patients (patients with AF =103; patients with paroxysmal supraventricular tachycardia =28). The impact of clinical risk factors and biomarkers on AF occurrence was evaluated using binary logistic analysis. RESULTS: The ELA expression level was lower in AF patients than in the negative controls (P<0.0001). Expression of ELA was negatively correlated with brain natriuretic peptide (BNP) expression in all the samples. In the binary logistic analysis, high levels of BNP and lower levels of ELA were significantly associated with an increased risk of AF (P<0.0001) and could be used as prognostic markers for patients with AF. CONCLUSIONS: Expression of ELA showed a protective role in AF patients. The ELA level was negatively correlated with BNP levels, which has been shown to predict a high risk of HF independently and consistently. Additionally, lower levels of ELA were associated with a high risk of AF and HF in patients with arrhythmia. KEYWORDS: ELABELA (ELA); matrix metalloproteinase-9 (MMP-9); tissue inhibitor of metalloproteinase-1 (TIMP-1); atrial fibrillation (AF); brain natriuretic peptide (BNP) AME Publishing Company 2021-12 /pmc/articles/PMC8743407/ /pubmed/35070372 http://dx.doi.org/10.21037/jtd-21-1728 Text en 2021 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Cui, Chunhong Zhou, Hongmei Xu, Jin ELABELA acts as a protective biomarker in patients with atrial fibrillation |
title | ELABELA acts as a protective biomarker in patients with atrial fibrillation |
title_full | ELABELA acts as a protective biomarker in patients with atrial fibrillation |
title_fullStr | ELABELA acts as a protective biomarker in patients with atrial fibrillation |
title_full_unstemmed | ELABELA acts as a protective biomarker in patients with atrial fibrillation |
title_short | ELABELA acts as a protective biomarker in patients with atrial fibrillation |
title_sort | elabela acts as a protective biomarker in patients with atrial fibrillation |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743407/ https://www.ncbi.nlm.nih.gov/pubmed/35070372 http://dx.doi.org/10.21037/jtd-21-1728 |
work_keys_str_mv | AT cuichunhong elabelaactsasaprotectivebiomarkerinpatientswithatrialfibrillation AT zhouhongmei elabelaactsasaprotectivebiomarkerinpatientswithatrialfibrillation AT xujin elabelaactsasaprotectivebiomarkerinpatientswithatrialfibrillation |